76. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia : an international journal of headache. 2011;31:18–30.
77. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J. Topiramate Chronic Migraine Study G. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double–blind, placebo–controlled trial, Headache. 2007;47:170–80.
78. Silberstein SD, Neto W, Schmitt J, Jacobs D, Group M–S. Topiramate in migraine prevention: results of a large controlled trial, Arch Neurol. 2004;61:490–5.
79. Holroyd KA, Cottrell CK, O’Donnell FJ, Cordingley GE, Drew JB, Carlson BW, Himawan L. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ (Clinical research ed). 2010;341:c4871.
80. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540–9.
81. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317–23.
82. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, Group C–I. Topiramate versus amitriptyline in migraine prevention: a 26– week, multicenter, randomized, double–blind, double–dummy, parallel–group noninferiority trial in adult migraineurs. Clin Ther. 2009;31:542–59.
83. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double–blind randomized placebo–controlled study. Clin Ter. 2000;151:145–8.
84. Feuerstein T, Quebe–Fehling E. A double–blind, placebo–controlled, parallel–group, multicenter study of the safety and efficacy of gabapentin (CI–945) as a prophylactic interval therapy in patients with common migraine (Protocols 879–201, –205, –206, –207, –209): Research Report No. RR 4301–00066. Freiburg: Goedecke AG Research and Development.; 1990.
85. Silberstein S, Goode–Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double– blind, placebo–controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia : an international journal of headache. 2013;33:101–11.
86. Moon HS, Park JW, Lee KS, Chung CS, Kim BK, Kim JM, Sohn JH, Chu MK, Oh K, Cho SJ. Clinical Features of Cluster Headache Patients in Korea. J Korean Med Sci.

두통 진료지침
<PAGE>64